Industrial Purity Specifications for (2R,3S)-3-Amino-2-Hydroxy-3-Phenylpropionic Acid
- Critical Sterechemistry: Strict control of (2R,3S) configuration is essential for Taxane API synthesis efficacy.
- Analytical Standards: Compliance requires chiral HPLC, NMR validation, and ICH Q7 aligned impurity profiling.
- Supply Chain: Bulk procurement demands verified COA, SDS, and stable cold-chain logistics for amino acid intermediates.
In the landscape of modern pharmaceutical manufacturing, the precision of chiral intermediates dictates the success of final Active Pharmaceutical Ingredients (APIs). Specifically, (2R,3S)-3-amino-2-hydroxy-3-phenylpropionic acid serves as a critical building block in the synthesis of complex antineoplastic agents, particularly within the Taxane class such as Cabazitaxel and Paclitaxel. For process chemists and procurement specialists, understanding the industrial purity specs is not merely a regulatory checkbox but a fundamental requirement for reaction yield optimization and downstream safety.
As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. adheres to rigorous quality control protocols to ensure that every batch meets the exacting standards required for GMP-compliant drug production. This technical overview details the essential specifications, analytical methods, and commercial considerations for sourcing this high-value intermediate.
Physicochemical Properties and Specification Table
Accurate characterization begins with defining the physical and chemical parameters of the molecule. Variations in moisture content or salt formation can significantly impact stoichiometry during scale-up. The following table outlines the standard industrial specifications for the free acid form, which is often converted to specific salts depending on the synthesis route employed by the API manufacturer.
| Parameter | Specification Standard | Test Method |
|---|---|---|
| CAS Number | 136561-53-0 | Registry Verification |
| Molecular Formula | C9H11NO3 | Calculated |
| Molecular Weight | 181.19 g/mol | Mass Spectrometry |
| Appearance | White to Off-White Crystalline Powder | Visual Inspection |
| Assay (Purity) | ≥ 98.5% (HPLC Area %) | HPLC |
| Chiral Purity | ≥ 99.0% ee | Chiral HPLC |
| Loss on Drying | ≤ 0.5% | Karl Fischer / LOD |
| Storage Temperature | 2-8°C (Protected from Light) | Stability Data |
Analytical Methods and Validation
Ensuring industrial purity requires a multi-faceted analytical approach. Standard reverse-phase HPLC is insufficient for chiral amino acids due to the presence of diastereomers and enantiomers that may co-elute under achiral conditions. Therefore, validation protocols must include chiral stationary phases to quantify the specific (2R,3S) isomer against potential (2S,3R) or meso impurities.
Chiral HPLC and NMR Confirmation
High-performance liquid chromatography using a chiral column is the industry standard for determining enantiomeric excess. Additionally, Nuclear Magnetic Resonance (NMR) spectroscopy provides structural confirmation, ensuring that the stereochemistry at the C2 and C3 positions aligns with the desired configuration. Any deviation here can lead to failed coupling reactions during the subsequent acylation steps in Taxane synthesis.
Impurity Profiling
According to ICH Q7 guidelines for API intermediates, known process-related impurities must be identified and quantified. Common impurities include unreacted starting materials, over-oxidation products, or hydrolysis byproducts. A comprehensive COA (Certificate of Analysis) should list these impurities with defined acceptance limits, typically not exceeding 0.10% for any single unknown impurity.
Manufacturing Process and Scalability
The synthesis route for (2R,3S)-3-Phenylisoserine often involves enzymatic resolution or asymmetric synthesis to achieve the necessary stereochemical purity. Industrial scalability depends on the robustness of this route. Batch-to-batch consistency is vital for pharmaceutical clients who require stable kinetics during their own manufacturing processes.
When evaluating suppliers, buyers should assess the manufacturer's capacity to maintain purity levels during scale-up from pilot plant to commercial tonnage. NINGBO INNO PHARMCHEM CO.,LTD. utilizes optimized fermentation and chemical synthesis hybrid processes to ensure high yields while minimizing environmental waste, aligning with modern green chemistry principles.
Documentation and Regulatory Compliance
Procurement of pharmaceutical intermediates extends beyond the physical product; it encompasses a suite of documentation required for regulatory filings. Key documents include:
- Safety Data Sheets (SDS): Must comply with GHS standards, detailing handling, storage, and disposal protocols.
- Product Specification (PS): A comprehensive breakdown of chemical composition, physical state, and acceptable quality ranges.
- Certificates of Origin (COO): Confirms the country of manufacture, which is critical for customs clearance and trade compliance.
Access to batch-specific documentation is non-negotiable. Clients should be able to retrieve historical COA data via lot number to track quality trends over time. This transparency builds trust and facilitates smoother audit processes during drug approval stages.
Commercial Considerations and Bulk Procurement
For large-scale API production, the bulk price is influenced by purity grades, packaging options, and logistical requirements. Amino acid derivatives often require cold-chain shipping to prevent degradation, which impacts overall landed cost. Establishing a long-term supply agreement with a reliable manufacturer mitigates the risk of production stoppages due to material shortages.
Procurement teams should prioritize suppliers who can demonstrate a stable supply chain and the ability to customize packaging, such as double-lined fiber drums or aluminum foil bags within HDPE containers, to ensure moisture protection. When sourcing high-purity (2R,3S)-3-Phenylisoserine, buyers should verify that the vendor maintains adequate inventory levels to support continuous manufacturing campaigns.
Conclusion
The integrity of the final pharmaceutical product relies heavily on the quality of its precursors. (2R,3S)-3-amino-3-phenyl-2-hydroxypropionic acid requires meticulous attention to stereochemistry, purity, and documentation. By partnering with a dedicated manufacturer that prioritizes technical excellence and regulatory compliance, pharmaceutical companies can secure a reliable supply chain for their critical Taxane intermediates. Ensuring these specifications are met from the outset prevents costly downstream processing issues and supports the timely delivery of life-saving medications to the global market.